New drug cocktail shows promise for tough lung cancers
NCT ID NCT01737502
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 19 times
Summary
This study tested a combination of two drugs, auranofin and sirolimus, in 29 people with advanced or recurrent lung cancer who had run out of standard treatment options. The goal was to find the best dose and see if the combo could slow cancer growth. The trial focused on safety and how long patients lived without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
Conditions
Explore the condition pages connected to this study.